These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 15951025

  • 1. The neutralizing epitope ELDKWA on HIV-1 gp41: genetic variability and antigenicity.
    Dong XN, Wu Y, Chen YH.
    Immunol Lett; 2005 Oct 15; 101(1):81-6. PubMed ID: 15951025
    [Abstract] [Full Text] [Related]

  • 2. Neutralizing epitopes in the membrane-proximal region of HIV-1 gp41: genetic variability and co-variation.
    Dong XN, Chen YH.
    Immunol Lett; 2006 Aug 15; 106(2):180-6. PubMed ID: 16859756
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems.
    Veiga AS, Pattenden LK, Fletcher JM, Castanho MA, Aguilar MI.
    Chembiochem; 2009 Apr 17; 10(6):1032-44. PubMed ID: 19283693
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA- and other two neutralizing-resistant mutated epitopes on HIV-1 gp41.
    Dong XN, Xiao Y, Chen YH.
    Immunol Lett; 2001 Jan 01; 75(2):149-52. PubMed ID: 11137140
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Binding antibody to neutralizing epitope gp41 in HIV-1 subtype CRF 01_AE infection related to stage of disease.
    Srisurapanon S, Louisirirotchanakul S, Sumransurp K, Ratanasrithong M, Chuenchitra T, Jintakatkorn S, Wasi C.
    Southeast Asian J Trop Med Public Health; 2005 Jan 01; 36(1):221-7. PubMed ID: 15906673
    [Abstract] [Full Text] [Related]

  • 10. ELDKWA-epitope-specific monoclonal antibodies inhibit HIV env-mediated syncytium formation.
    Zhang G, Chen YH.
    Immunobiology; 2003 Jan 01; 207(4):259-64. PubMed ID: 12952348
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy.
    Liu Z, Chen YH.
    J Immunol Methods; 2004 Feb 01; 285(1):93-7. PubMed ID: 14871538
    [Abstract] [Full Text] [Related]

  • 14. Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.
    Bryson S, Julien JP, Isenman DE, Kunert R, Katinger H, Pai EF.
    J Mol Biol; 2008 Oct 17; 382(4):910-9. PubMed ID: 18692506
    [Abstract] [Full Text] [Related]

  • 15. Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
    Li J, Chen X, Jiang S, Chen YH.
    Biochem Biophys Res Commun; 2008 Nov 07; 376(1):60-4. PubMed ID: 18762167
    [Abstract] [Full Text] [Related]

  • 16. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site.
    Julien JP, Bryson S, Nieva JL, Pai EF.
    J Mol Biol; 2008 Dec 12; 384(2):377-92. PubMed ID: 18824005
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.